János L. Tanyi

9.6k total citations · 1 hit paper
113 papers, 3.9k citations indexed

About

János L. Tanyi is a scholar working on Oncology, Molecular Biology and Reproductive Medicine. According to data from OpenAlex, János L. Tanyi has authored 113 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Oncology, 36 papers in Molecular Biology and 30 papers in Reproductive Medicine. Recurrent topics in János L. Tanyi's work include Ovarian cancer diagnosis and treatment (30 papers), CAR-T cell therapy research (19 papers) and Immunotherapy and Immune Responses (17 papers). János L. Tanyi is often cited by papers focused on Ovarian cancer diagnosis and treatment (30 papers), CAR-T cell therapy research (19 papers) and Immunotherapy and Immune Responses (17 papers). János L. Tanyi collaborates with scholars based in United States, Hungary and Canada. János L. Tanyi's co-authors include Kathleen T. Montone, George Coukos, Gordon B. Mills, Lana E. Kandalaft, Zhongyi Hu, Carl H. June, Lin Zhang, Drew A. Torigian, Bruce L. Levine and Mark A. Morgan and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

János L. Tanyi

107 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

2021 186 citations János L. Tanyi et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
János L. Tanyi United States	36	1.9k	1.7k	887	720	523	113	3.9k
Paulette Mhawech‐Fauceglia United States	35	1.9k 1.0×	2.0k 1.2×	1.6k 1.8×	689 1.0×	651 1.2×	126	5.0k
Delia Mezzanzanica Italy	37	2.0k 1.0×	1.3k 0.7×	1.0k 1.2×	889 1.2×	472 0.9×	107	3.9k
Kimberly R. Kalli United States	46	2.2k 1.2×	2.1k 1.2×	1.6k 1.8×	1.1k 1.5×	1.0k 2.0×	101	5.5k
Joan G. Jones United States	31	2.0k 1.1×	2.2k 1.3×	1.1k 1.3×	1.1k 1.5×	287 0.5×	70	4.9k
Christina M. Annunziata United States	37	2.5k 1.3×	2.6k 1.6×	1.2k 1.3×	1.0k 1.4×	1.1k 2.1×	155	5.4k
Akihiro Nawa Japan	33	1.5k 0.8×	1.5k 0.9×	649 0.7×	614 0.9×	720 1.4×	111	3.8k
Daniel Rosen United States	37	2.6k 1.4×	1.5k 0.9×	608 0.7×	1.0k 1.4×	1.0k 1.9×	87	4.9k
Hilary A. Kenny United States	27	2.6k 1.4×	1.8k 1.1×	1.1k 1.2×	2.1k 2.9×	781 1.5×	41	5.4k
Paul Haluska United States	38	2.5k 1.3×	2.0k 1.2×	497 0.6×	1.1k 1.6×	411 0.8×	114	4.9k
Aurelia Noske Germany	38	3.2k 1.7×	3.2k 1.9×	950 1.1×	1.9k 2.7×	661 1.3×	102	6.8k

Countries citing papers authored by János L. Tanyi

Since Specialization

Citations

This map shows the geographic impact of János L. Tanyi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by János L. Tanyi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites János L. Tanyi more than expected).

Fields of papers citing papers by János L. Tanyi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by János L. Tanyi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by János L. Tanyi. The network helps show where János L. Tanyi may publish in the future.

Co-authorship network of co-authors of János L. Tanyi

This figure shows the co-authorship network connecting the top 25 collaborators of János L. Tanyi. A scholar is included among the top collaborators of János L. Tanyi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with János L. Tanyi. János L. Tanyi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tanyi, János L., et al.. (2025). Pembrolizumab-associated Guillain-Barre syndrome in a patient with endometrial cancer: A case report. Gynecologic Oncology Reports. 60. 101816–101816.

Nasioudis, Dimitrios, et al.. (2024). CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now?. Diagnostics. 14(8). 819–819. 11 indexed citations

Dao, Minh, Emese Zsíros, Renata R. Urban, et al.. (2023). Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study. European Journal of Gynaecological Oncology. 44(1). 17–25. 6 indexed citations

Wethington, Stephanie L., Payal D. Shah, Lainie P. Martin, et al.. (2023). C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer. Clinical Cancer Research. 29(15). 2800–2807. 40 indexed citations

Tanyi, János L., Leslie M. Randall, Setsuko K. Chambers, et al.. (2023). A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor–Positive Ovarian Cancer (Study 006). Obstetrical & Gynecological Survey. 78(6). 341–342.

Tanyi, János L., Mark H. O’Hara, Elizabeth O. Hexner, et al.. (2023). 671 Phase 1 trial of human chimeric antigen receptor modified T cells (huCART-meso) administered in combination with oncolytic virus VCN-01 in patients with pancreatic and ovarian cancer. SHILAP Revista de lepidopterología. A760–A761.

Ferrari, Adam J., Akshaya V. Annapragada, Yasuto Kinose, et al.. (2023). H2Bub1 loss is an early contributor to clear cell ovarian cancer progression. JCI Insight. 8(12). 4 indexed citations

O’Cearbhaill, Roisin E., Michael W. Sill, Steven Waggoner, et al.. (2023). PO005LBA/#1579 A randomized, phase II/III study of pegylated-liposomal-doxorubicin and atezolizumab (IND #134427) versus pegylated-liposomal-doxorubicin, bevacizumab and atezolizumab versus pegylated-liposomal-doxorubicin and bevacizumab in platinum-resistant ovarian cancer (NRG-GY009). A4–A4.

Jiang, Junjie, Jiao Yuan, Zhongyi Hu, et al.. (2022). Systematic illumination of druggable genes in cancer genomes. Cell Reports. 38(8). 110400–110400. 24 indexed citations

10.

Hu, Zhongyi, Jiao Yuan, Meixiao Long, et al.. (2021). The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets. Nature Cancer. 2(12). 1406–1422. 61 indexed citations

11.

Pierini, Stefano, János L. Tanyi, Fiona Simpkins, et al.. (2020). Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target. JCI Insight. 5(16). 19 indexed citations

12.

Lin, Xiaojuan, Jianfeng Shen, Dan Peng, et al.. (2018). RNA-binding protein LIN28B inhibits apoptosis through regulation of the AKT2/FOXO3A/BIM axis in ovarian cancer cells. Signal Transduction and Targeted Therapy. 3(1). 23–23. 45 indexed citations

13.

Yang, Lu, Youyou Zhang, Weiwei Shan, et al.. (2017). Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition. Science Translational Medicine. 9(400). 181 indexed citations

14.

Zsíros, Emese, Priyanka Duttagupta, Denarda Dangaj Laniti, et al.. (2015). The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28–Costimulated T Cells Prepared for Adoptive Therapy. Clinical Cancer Research. 21(12). 2840–2850. 48 indexed citations

15.

Chiang, Cheryl Lai-Lai, Lana E. Kandalaft, János L. Tanyi, et al.. (2013). A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside. Clinical Cancer Research. 19(17). 4801–4815. 181 indexed citations

16.

Hu, Zhongyi, Lan Zheng, Chunsheng Li, et al.. (2013). The Heterochronic microRNA let-7 Inhibits Cell Motility by Regulating the Genes in the Actin Cytoskeleton Pathway in Breast Cancer. Molecular Cancer Research. 11(3). 240–250. 90 indexed citations

17.

Kandalaft, Lana E., Cheryl Lai-Lai Chiang, János L. Tanyi, et al.. (2013). A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. Journal of Translational Medicine. 11(1). 149–149. 53 indexed citations

18.

Li, Ning, Xiaomin Zhong, Xiaojuan Lin, et al.. (2012). Lin-28 Homologue A (LIN28A) Promotes Cell Cycle Progression via Regulation of Cyclin-dependent Kinase 2 (CDK2), Cyclin D1 (CCND1), and Cell Division Cycle 25 Homolog A (CDC25A) Expression in Cancer. Journal of Biological Chemistry. 287(21). 17386–17397. 59 indexed citations

19.

Tanyi, János L., et al.. (2006). Primary Neuroendocrine Carcinoma of the Vagina With Merkel Cell Carcinoma Phenotype. The American Journal of Surgical Pathology. 30(3). 405–410. 29 indexed citations

20.

Tanyi, János L., Anikó Páy, János Rigó, Bálint Nagy, & Z. Papp. (1985). [Mutation analysis of the beta-catenin gene in epithelial carcinomas of the ovaries].. PubMed. 141(2). 1115–299. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact